
Eli Lilly and Company
LLYHealthcare|Drug Manufacturers - General|US
$1354.00
-10.73 (-0.79%)
DCF Value
$771.70
Tangible Book / Share
$13.81
Graham Number
$177.24
Cash / Share
$5.48
Clinical Trials (500)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT04372277 Taltz in Combination With Enstilar for Psoriasis | Psoriasis | P4 | Recruiting | 25 | Open-label | Enstilar |
| NCT07613294 A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk | Atherosclerosis, Cardiovascular Diseases | P3 | Recruiting | 252 | RCT, Double-blind | Lepodisiran, Placebo |
| NCT06972472 A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes | Obesity, Overweight | P3 | Active | 600 | RCT, Double-blind | Orforglipron, Placebo |
| NCT06383390 The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) | Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD) | P3 | Active | 10,000 | RCT, Double-blind | Retatrutide, Placebo |
| NCT05559359 A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis | Atopic Dermatitis, Eczema | P3 | Active | 377 | RCT, Double-blind | Lebrikizumab, Placebo, Topical Corticosteroid (TCS) |
| NCT07279688 Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumatica | Polymyalgia Rheumatica (PMR) | P3 | Recruiting | 140 | RCT, Double-blind | Baricitinib 4 MG Oral Tablet, Baricitinib 2 MG Oral Tablet, Placebo 4 mg, Placebo 2 mg |
| NCT06260722 Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2) | Diabetes Mellitus, Type 2 | P3 | Active | 1,250 | RCT, Open-label | Retatrutide, Semaglutide |
| NCT05509777 A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease | Crohn's Disease | P3 | Recruiting | 90 | Open-label | Mirikizumab |
| NCT05508789 A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5) | Alzheimer Disease, Dementia | P3 | Active | 1,500 | RCT, Double-blind | Donanemab, Placebo |
| NCT07157774 Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) | Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD) | P3 | Recruiting | 10,450 | RCT, Double-blind | Muvalaplin, Placebo |
| NCT07321886 A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes | Obesity, Overweight | P3 | Recruiting | 1,980 | RCT, Double-blind | Eloralintide, Placebo |
| NCT07222332 A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE) | Diabetes Mellitus, Type 1 | P3 | Recruiting | 300 | RCT, Double-blind | Baricitinib, Placebo |
| NCT06672939 A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities | Obesity, Overweight | P3 | Recruiting | 150 | RCT, Double-blind | Orforglipron, Placebo |
| NCT02763566 A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer | Breast Cancer | P3 | Active | 463 | RCT, Double-blind | Abemaciclib, Anastrozole, Letrozole, Placebo, Fulvestrant |
| NCT07219953 A Study of Brenipatide in Participants With Alcohol Use Disorder | Alcohol Use Disorder | P3 | Recruiting | 1,100 | RCT, Double-blind | LY3537031, Placebo |
| NCT06075667 A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities | Obesity, Overweight | P3 | Active | 160 | RCT, Double-blind | Tirzepatide, Placebo |
| NCT05026866 A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) | Alzheimer Disease | P3 | Active | 2,996 | RCT, Double-blind | Donanemab, Placebo |
| NCT07817875 Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS) | Obesity | P3 | Recruiting | 150 | RCT, Double-blind | Tirzepatide, Placebo |
| NCT06937099 Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight | Crohn's Disease, Obesity or Overweight | P3 | Recruiting | 290 | RCT, Double-blind | Mirikizumab, Mirikizumab, Tirzepatide, Placebo |
| NCT06937086 Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study | Ulcerative Colitis, Obesity or Overweight | P3 | Recruiting | 350 | RCT, Double-blind | Mirikizumab, Mirikizumab, Tirzepatide, Placebo |
| NCT07571161 Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease | Alzheimer Disease | P3 | Recruiting | 140 | RCT, Double-blind | Donanemab, Placebo |
| NCT06859268 A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity | Obesity | P3 | Active | 643 | RCT, Double-blind | Retatrutide, Placebo |
| NCT04956640 Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms | P1P2 | Active | 540 | Open-label | LY3537982, Pembrolizumab, Cetuximab, Pemetrexed, Cisplatin, Carboplatin |
| NCT07269210 A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia | Severe Hypertriglyceridemia | P2 | Recruiting | 60 | RCT, Double-blind | Solbinsiran, Placebo |
| NCT04469764 Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer | Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma | P2 | Recruiting | 32 | Open-label | Abemaciclib, Anastrozole, Letrozole |
| NCT07415044 LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis | Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate | P2 | Recruiting | 1,431 | RCT, Double-blind | LY4268989, Placebo |
| NCT07287098 A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer | Breast Neoplasms | P2 | Recruiting | 600 | RCT, Open-label | Imlunestrant, Goserelin, Tamoxifen 20 mg |
| NCT02981940 A Study of Abemaciclib in Recurrent Glioblastoma | Glioblastoma | P2 | Active | 45 | Open-label | Abemaciclib |
| NCT04623541 Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome | Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | P1P2 | Active | 194 | Open-label | Epcoritamab, Epcoritamab, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, Venetoclax, Epcoritamab, Lenalidomide, Epcoritamab, Pirtobrutinib, Epcoritamab |
| NCT07219173 A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma | Asthma | P2 | Recruiting | 531 | RCT, Double-blind | Brenipatide, Brenipatide, Placebo |
| NCT07698210 A Study of LY4178256 in Healthy Participants | Healthy Volunteers | P1 | Recruiting | 88 | RCT, Double-blind | LY4178256, Placebo |
| NCT07547540 A Study of LY3971297 in Participants With Heart Failure | Heart Failure, Heart Failure, Diastolic | P1 | Recruiting | 90 | RCT, Single-blind | LY3971297, LY3971297, Placebo, Placebo |
| NCT07787169 A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease | Alzheimer Disease, Amyloid | P1 | Recruiting | 179 | RCT, Double-blind | LY4405094, LY4405094, Placebo, Placebo |
| NCT07165002 A Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver Impairment | Healthy, Hepatic Insufficiency | P1 | Recruiting | 32 | Open-label | LY3537031 |
| NCT04603001 Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations | Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) | P1 | Active | 260 | Open-label | LY3410738, Venetoclax, Azacitidine |
| NCT06982859 A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus | Diabetes Mellitus, Insulin Sensitivity | P1 | Active | 95 | RCT, Double-blind | Retatrutide, Semaglutide, Placebo |
| NCT07566338 A Study of LY4302814 in Healthy Participants | Healthy | P1 | Recruiting | 150 | RCT, Double-blind | LY4302814, LY4302814, Placebo, Placebo |
| NCT07654972 A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy | Obesity, Overweight | P1 | Recruiting | 116 | RCT, Double-blind | LY4174794, LY4174794, Placebo |
| NCT07801300 A Study of LY5625575 in Healthy Participants and in Participants With Inflammation (Elevated C-Reactive Protein) | Healthy Volunteers, C-Reactive Protein | P1 | Recruiting | 204 | RCT, Double-blind | LY5625575, Placebo |
| NCT07476118 A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity | Obesity, Overweight | P1 | Active | 150 | RCT, Double-blind | Brenipatide |
| NCT06678269 A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer | Metastatic Breast Cancer, Stage IV Breast Cancer | P1 | Recruiting | 28 | Open-label | Abemaciclib |
| NCT06343805 A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i) | Primary Myelofibrosis | P1 | Recruiting | 256 | Open-label | LY5830966 |
| NCT07258849 A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis | Rheumatoid Arthritis (RA) | P1 | Recruiting | 141 | RCT, Open-label | LY4213663, LY4213663, Placebo, Placebo |
| NCT07767487 A Study of LY4226695 in Healthy Participants | Healthy | P1 | Recruiting | 148 | RCT, Double-blind | LY4226695, LY4226695, Placebo |
| NCT00414115 National Active Surveillance Network and Pharmacogenomics of Adverse Drug Reactions in Children | Adverse Drug Reaction (ADR) | Recruiting | 7,000 | — | — | |
| NCT03958136 Clinico-biological Data Collection Study of Metastatic Breast Cancer | Breast Cancer | N/A | Active | 289 | Open-label | Biomarkers blood, urine and microbiota samples |
| NCT07063316 SGLT2 Inhibitors and Renal Anemia in Japan: RWD | Chronic Kidney Disease | Active | 15,000 | — | SGLT2 inhibitor | |
| NCT06991946 Patient-Centric Study to Assess the Impact of Genomic Profiling on the Treatment of Patients With Metastatic Breast Cancer in Spain | Metastatic Breast Cancer | Recruiting | 300 | — | — | |
| NCT03549416 BioDay Registry: Data Collection Regarding the Use of New Systemic Treatment Options in Patients with Atopic Dermatitis | Atopic Dermatitis | Recruiting | 1,200 | — | — | |
| NCT06566170 A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease | Alzheimer Disease | Recruiting | 6,250 | — | Donanemab, Usual Care | |
| NCT00206375 Growth Hormone and GnRH Agonist in Adolescents With Acquired Hypothyroidism | Hypothyroidism | P4 | Terminated | 16 | RCT, Open-label | Growth hormone, Growth hormone treatment and puberty |
| NCT00422162 A Study Evaluating Duloxetine in Patients Hospitalized for Severe Depression | Major Depressive Disorder | P4 | Completed | 339 | RCT, Double-blind | Duloxetine hydrochloride, Placebo |
| NCT00716274 Effects of Atomoxetine on Brain Activation During Attention & Reading Tasks in Participants With ADHD & Comorbid Dyslexia | Attention Deficit Hyperactivity Disorder, Dyslexia | P4 | Completed | 110 | RCT, Double-blind | Atomoxetine, Placebo |
| NCT00190736 Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults With ADHD Over an Extended Period of Time (6 Months) | ADHD | P4 | Completed | 440 | RCT, Double-blind | Atomoxetine Hydrochloride, placebo |
| NCT00067912 Duloxetine vs. Active Comparator for the Treatment of Depression | Depression | P4 | Completed | 480 | RCT, Double-blind | Duloxetine Hydrochloride, Venlafaxine Extended Release |
| NCT06901518 The Effect of Galcanezumab-gnlm on Post-Traumatic, Migrainous Headaches | Post-Traumatic Headache | P4 | Completed | 25 | Open-label | Galcanezumab-Gnlm |
| NCT00191464 Long-Term Effects of Insulin Plus Metformin Regimens on the Overall and Postprandial Glycemic Control of Patients With Type 2 Diabetes | Diabetes Mellitus, Type 2 | P4 | Completed | 320 | RCT, Open-label | premeal insulin lispro mixtures, insulin glargine, metformin |
| NCT00477581 A Study to Compare the Effects of Exenatide and Sitagliptin on Postprandial Glucose in Subjects With Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus | P4 | Completed | 102 | RCT, Double-blind | exenatide, sitagliptin |
| NCT04271202 Novel Insight Into Migraine Pathophysiolgy and Galcanezumab Mechanisms of Action | Chronic Migraine | P4 | Completed | 64 | Open-label | Emgality 120 MG in 1 ML Prefilled Syringe |
| NCT00191399 Bipolar Depression Study: Bipolar Depression Assessment Study on Treatment Response | Depression, Bipolar | P4 | Completed | 150 | RCT, Open-label | Olanzapine, Fluoxetine |
| NCT03573323 A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis | Plaque Psoriasis | P4 | Completed | 1,027 | RCT, Double-blind | Ixekizumab, Guselkumab, Placebo |
| NCT00100776 Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder | Schizophrenia, Schizoaffective Disorder | P4 | Completed | 600 | RCT, Double-blind | Olanzapine |
| NCT01774968 Study of Human Regular U-500 Insulin in Adult Participants With Type 2 Diabetes | Diabetes Mellitus, Type 2 | P4 | Completed | 325 | RCT, Open-label | Human Regular U-500 Insulin |
| NCT00870194 A Comparison of Adding Exenatide With Switching to Exenatide in Patients With Type 2 Diabetes Experiencing Inadequate Glycemic Control With Sitagliptin Plus Metformin | Type 2 Diabetes Mellitus | P4 | Completed | 255 | RCT, Double-blind | exenatide and sitagliptin, exenatide and placebo |
| NCT04086745 A Study of Baricitinib in Participants With Rheumatoid Arthritis | Rheumatoid Arthritis | P4 | Completed | 1,050 | RCT, Open-label | Baricitinib, TNF Inhibitor |
| NCT00485849 A Study of Atomoxetine for Attention Deficit and Hyperactive/Impulsive Behaviour Problems in Children With ASD | Attention Deficit Hyperactivity Disorder | P4 | Completed | 12 | Open-label | Atomoxetine Hydrochloride |
| NCT05080218 COVID-19 VaccinE Response in Rheumatology Patients | Rheumatoid Arthritis, Psoriatic Arthritis | P4 | Completed | 841 | RCT, Open-label | Upadacitinib, Abatacept, Secukinumab, Tofacitinib, TNF Inhibitor, Canakinumab Injection, Baricitinib, Ixekizumab |
| NCT00191178 Effects of Insulin in Perceived Mood Symptoms in Patients With Type 2 Diabetes | Type 2 Diabetes | P4 | Completed | 60 | RCT, Open-label | insulin lispro protamine suspension:insulin lispro rDNA origin low mix, insulin glargine |
| NCT00266643 Tolerability of Switching to Duloxetine for the Management of Diabetic Nerve Pain | Diabetic Neuropathy, Painful | P4 | Completed | 205 | RCT, Double-blind | duloxetine hydrochloride |
| NCT00188942 A Neuroimaging Investigation of Brain Activity in Major Depressive Disorder and Bipolar Disorder | Major Depressive Disorder | P4 | Completed | 42 | Open-label | Fluoxetine+Olanzapine, Olanzapine |
| NCT00216918 Neuropsychological Functioning in Children With Attention-Deficit/Hyperactivity Disorder. | Attention Deficit Hyperactivity Disorder | P4 | Completed | 40 | Open-label | Atomoxetine Hydrochloride |
| NCT00191282 Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes | Diabetes Mellitus, Type 2, Acute Myocardial Infarction | P4 | Completed | 1,116 | RCT, Open-label | Insulin lispro, Human insulin isophane suspension (NPH), Insulin glargine, Human insulin isophane suspension, Human insulin 30/70 |
| NCT00488163 Pilot Study of Atomoxetine To Enhance COgnition In Patients With Schizophrenia | Schizophrenia | P4 | Completed | 20 | RCT, Double-blind | Atomoxetine |
| NCT00252278 Effect of Atomoxetine on ADHD-Related Insomnia in Children and Adolescents | Attention-Deficit/Hyperactivity Disorder (ADHD), Insomnia | P4 | Unknown | 36 | RCT, Double-blind | atomoxetine |
| NCT01391221 Inflammatory Markers and Cognitive Function in Major Depression | Major Depression | P4 | Unknown | 20 | Open-label | Duloxetine |
| NCT01703702 Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline | Alzheimer's Disease | P4 | Completed | 641 | RCT, Open-label | florbetapir (18F) |
| NCT00420095 A Study for Patients With Diabetes Mellitus (IOPA) | Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | P4 | Completed | 117 | RCT, Open-label | Human insulin 30/70, Insulin lispro low mix |
| NCT00394095 Topiramate vs. Placebo in Preventing Weight Gain in Bipolar Disorder Treated With Olanzapine | Bipolar Disorder, Weight Gain | P4 | Completed | 31 | RCT, Double-blind | Topiramate, Placebo |
| NCT00696293 Duloxetine Treatment of Major Depression and Chronic Low Back Pain For Older Adults | Major Depressive Disorder, Back Pain | P4 | Completed | 30 | Open-label | Duloxetine |
| NCT00380718 Chemotherapy for Patients With Non-Small Cell Lung Cancer | Non-small Cell Lung Cancer | P4 | Completed | 33 | Open-label | pemetrexed |
| NCT00960986 A Duloxetine Dosing Strategy Study in Korean Patients With Major Depressive Disorder | Major Depressive Disorder (MDD) | P4 | Completed | 249 | RCT, Open-label | Duloxetine hydrochloride |
| NCT04707196 A Study of Abemaciclib in Indian Women With Advanced Breast Cancer | Breast Neoplasms, Neoplasm Metastasis | P4 | Completed | 200 | Open-label | Abemaciclib, Nonsteroidal Aromatase Inhibitor (NSAI), Fulvestrant |
| NCT00485498 Managing Acute Schizophrenia, a Comparison Between Two Atypical Antipsychotics | Schizophrenia | P4 | Completed | 122 | RCT, Double-blind | Olanzapine Hydrochloride, Risperidone |
| NCT00169065 Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia | Schizophrenia | P4 | Completed | 38 | RCT, Single-blind | Clozapine, Olanzapine |
| NCT00049777 A Trial of Heparin in Patients With Severe Sepsis Who Are Undergoing Treatment With Drotrecogin Alfa (Activated) | Sepsis | P4 | Completed | 2,000 | RCT, Double-blind | Drotrecogin Alfa (Activated), Unfractionated heparin, Low molecular weight heparin |
| NCT00279201 The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV) | Diabetes Mellitus, Type 2 | P4 | Completed | 2,091 | RCT, Open-label | Insulin glargine, Lispro Low Mix, Lispro Mid Mix, Lispro |
| NCT00440895 A Randomized Trial of Early Discharge After Trans-radial Stenting of Coronary Arteries in Acute MI and Rescue-PCI | Myocardial Infarction, Ischemia | P4 | Completed | 74 | RCT, Double-blind | Abciximab |
| NCT06635057 A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan | Type 2 Diabetes | P4 | Completed | 166 | Open-label | Tirzepatide |
| NCT00532428 Long Term Effects of Raloxifene Treatment on Bone Quality | Osteoporosis, Post-Menopausal | P4 | Completed | 31 | RCT, Double-blind | Raloxifene, Raloxifene, Placebo |
| NCT01451606 Duloxetine for the Treatment of Chronic Pelvic Pain | Pelvis Pain Chronic | P4 | Terminated | 34 | RCT, Double-blind | Duloxetine, Placebo |
| NCT02240680 Linagliptin as Add on to Basal Insulin in the Elderly | Diabetes Mellitus, Type 2 | P4 | Completed | 302 | RCT, Double-blind | placebo, linagliptin |
| NCT00485862 Combination Therapy in Patients With Depression | Depressive Symptoms | P4 | Completed | 214 | RCT, Double-blind | Atomoxetine Hydrochloride, Sertraline, Placebo |
| NCT00191061 A Comparison of Tolerability and Efficacy of Different Doses of Duloxetine for the Treatment of Major Depressive Disorder | Depressive Disorder | P4 | Completed | 640 | RCT, Double-blind | duloxetine hydrochloride |
| NCT00239629 Teriparatide and Strontium Ranelate Head-To-Head Comparison Trial | Postmenopausal Osteoporosis | P4 | Completed | 73 | RCT, Open-label | Teriparatide, Strontium ranelate |
| NCT01118780 A Study of Duloxetine in Elderly Generalized Anxiety Disorder | Generalized Anxiety Disorder | P4 | Completed | 291 | RCT, Double-blind | Duloxetine, Placebo |
| NCT00673452 A Study Comparing Duloxetine and Placebo in the Treatment of Fibromyalgia | Fibromyalgia | P4 | Completed | 530 | RCT, Double-blind | duloxetine hydrochloride, placebo |
| NCT00181948 Strattera Treatment in Children With ADHD Who Have Poor Response to Stimulant Therapy | ADHD | P4 | Completed | 30 | Open-label | atomoxetine (Strattera) |
| NCT01430104 A Study of Teriparatide in Japanese Osteoporosis Patients | Osteoporosis | P4 | Completed | 30 | Open-label | Teriparatide, Aspara-CA 600 mg, Alfarol 1.0 µg |
| NCT00079924 Effects of Teriparatide in Postmenopausal Women With Osteoporosis | Postmenopausal Osteoporosis | P4 | Completed | 200 | RCT, Open-label | teriparatide, aldrenodate, raloxifene |
| NCT05002127 A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | P2P3 | Completed | 127 | RCT, Double-blind | Evorpacept (ALX148), Trastuzumab, Ramucirumab, Paclitaxel |
| NCT04809220 A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes | Diabetes Mellitus, Diabetes Mellitus, Type 2 | P3 | Completed | 591 | RCT, Double-blind | Dulaglutide, Oral antihyperglycemics |
| NCT00976456 Efficacy Study of Avastin® With Pemetrexed +/- Carboplatin to Treat Elderly Patients With Non-small Cell Lung Cancer | Non-squamous Non-small Cell Lung Cancer | P3 | Completed | 271 | RCT, Open-label | Bevacizumab + Pemetrexed, Bevacizumab + Pemetrexed + Carboplatin |
| NCT01139762 A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms | Benign Prostatic Hyperplasia, Enlarged Prostate | P3 | Completed | 696 | RCT, Double-blind | Tadalafil, Placebo, Finasteride |
| NCT02132637 A Study to Compare the Effect of a Double Dose of Two Long-acting Insulin Therapies in Participants With Type 2 Diabetes | Type 2 Diabetes Mellitus | P3 | Completed | 68 | RCT, Double-blind | Insulin Peglispro, Insulin Glargine |
| NCT00816959 Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma | Hodgkin's Lymphoma | P3 | Unknown | 1,200 | RCT, Open-label | R-mabHDI and ABVD, ABVD |
| NCT03214380 A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes | Type 2 Diabetes Mellitus | P3 | Completed | 933 | RCT, Double-blind | LY900014, Insulin Lispro, Insulin Glargine, Insulin Degludec, Metformin, SGLT2 inhibitor |
| NCT03524092 A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis | Ulcerative Colitis | P3 | Completed | 1,328 | Double-blind | Mirikizumab SC, Mirikizumab IV, Placebo SC |
| NCT02783573 A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia | Alzheimer's Disease | P3 | Terminated | 1,722 | RCT, Double-blind | Lanabecestat, Placebo |
| NCT00421083 Efficacy and Safety of Tadalafil in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury | Erectile Dysfunction, Spinal Cord Injuries | P3 | Completed | 180 | RCT, Double-blind | tadalafil |
| NCT00190788 Extended Therapy of Drotrecogin Alfa (Activated) 4 vs 7 Days Infusion | Sepsis, Hypotension | P3 | Completed | 200 | RCT, Double-blind | Drotrecogin Alfa (Activated), placebo |
| NCT03433677 A Study of LY900014 and Insulin Lispro With an External Continuous Subcutaneous Insulin Infusion System in Adult Participants With Type 1 Diabetes | Diabetes Type 1 | P3 | Completed | 49 | RCT, Double-blind | LY900014, Insulin lispro |
| NCT00332202 PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin | Non Hodgkin Lymphoma | P3 | Completed | 758 | RCT, Double-blind | enzastaurin, placebo |
| NCT01015287 A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction | Acute Coronary Syndromes | P3 | Completed | 4,033 | RCT, Double-blind | Placebo, Prasugrel |
| NCT00970632 A Study of Tadalafil in Men With Benign Prostatic Hyperplasia | Benign Prostatic Hyperplasia (BPH) | P3 | Completed | 511 | RCT, Double-blind | Tadalafil 5 mg, Placebo tablet, Tamsulosin, Placebo capsule |
| NCT00485407 Guiding Dose Increases in Patients Incompletely Responsive to Usual Doses of Atomoxetine | Attention Deficit Hyperactivity Disorder | P3 | Completed | 377 | RCT, Double-blind | Atomoxetine Hydrochloride |
| NCT02760602 A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease | Alzheimer's Disease | P3 | Terminated | 26 | RCT, Double-blind | Solanezumab, Placebo |
| NCT01177813 Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes | Diabetes Mellitus, Type 2 | P3 | Completed | 986 | RCT, Double-blind | Placebo identical to BI10773 high dose, BI 10773, BI 10773 open label, Placebo identical to BI10773 low dose, Placebo identical to BI10773 low dose, Placebo identical to BI10773 high dose, Placebo identical to Sitagliptin 100mg, Placebo identical to Sitagliptin 100mg, BI10773, Sitagliptin, Placebo identical to Sitagliptin 100mg, Placebo identical to BI10773 low dose, Placebo identical to BI10773 high dose |
| NCT00359879 Comparison of Exenatide Taken Before Lunch and Dinner With Before Breakfast and Dinner in Patients With Type 2 Diabetes | Type 2 Diabetes | P3 | Completed | 377 | RCT, Open-label | exenatide, exenatide |
| NCT00190996 Evaluate Safety and Efficacy of Duloxetine in Predominant Stress Urinary Incontinence | Urinary Incontinence, Stress | P3 | Completed | 2,765 | RCT, Double-blind | Duloxetine Hydrochloride, placebo |
| NCT00191113 Somatropin Treatment to Final Height in Turner Syndrome | Turner Syndrome | P3 | Completed | 154 | RCT, Open-label | Somatropin, Ethinyl estradiol, Medroxyprogesterone acetate |
| NCT02528253 A Phase 3 Study of Tanezumab for Chronic Low Back Pain | Low Back Pain | P3 | Completed | 1,832 | RCT, Double-blind | Placebo to Week 16; tanezumab 5mg SC, Placebo to Week 16, tanezumab 10 mg SC, Tanezumab 5 mg SC, Tanezumab 10 mg SC, Tramadol PR oral |
| NCT01215942 An Open Label Study for Participants With Rheumatoid Arthritis | Rheumatoid Arthritis | P3 | Terminated | 1,086 | RCT, Open-label | LY2127399 |
| NCT03926130 A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease | Crohn's Disease | P3 | Completed | 1,158 | RCT, Double-blind | Mirikizumab, Mirikizumab, Ustekinumab, Ustekinumab, Placebo, Placebo |
| NCT00262769 Gemcitabine With or Without Cisplatin in Treating Patients With Unresectable Locally Advanced or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors | Extrahepatic Bile Duct Cancer, Gallbladder Cancer | P3 | Completed | 324 | RCT, Open-label | cisplatin, gemcitabine hydrochloride |
| NCT04392154 Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) | Atopic Dermatitis | P3 | Completed | 1,153 | Double-blind | Lebrikizumab |
| NCT01646177 A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3) | Psoriasis | P3 | Completed | 1,346 | RCT, Double-blind | Placebo, 50 mg etanercept, 80 mg ixekizumab |
| NCT02580591 Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3) | Diabetes Mellitus, Type 1 | P3 | Completed | 977 | RCT, Double-blind | Empagliflozin, Placebo |
| NCT04146363 Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1) | Atopic Dermatitis | P3 | Completed | 424 | RCT, Double-blind | Lebrikizumab |
| NCT02696785 A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis | Spondyloarthritis | P3 | Completed | 341 | RCT, Double-blind | Ixekizumab, Placebo, Adalimumab |
| NCT02963766 A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes | Type 2 Diabetes | P3 | Completed | 154 | RCT, Double-blind | Dulaglutide, Placebo |
| NCT00191529 Growth Hormone Treatment in Short Children Born Small for Gestational Age | Infant, Small for Gestational Age | P3 | Completed | 200 | RCT, Open-label | somatropin |
| NCT01204294 Comprehensive Add on Study in Japan | Diabetes Mellitus, Type 2 | P3 | Completed | 574 | RCT, Open-label | Linagliptin, Linagliptin, Metformin, Metformin, Linagliptin, Linagliptin, Linagliptin |
| NCT06588296 Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight | Psoriatic Arthritis, Obesity | P3 | Completed | 279 | RCT, Open-label | Ixekizumab, Tirzepatide |
| NCT00035035 A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas. | Pancreatic Neoplasms, Metastases, Neoplasm | P3 | Completed | — | RCT, Open-label | GEMZAR, ALIMTA |
| NCT00762411 Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo | Alzheimer's Disease | P3 | Completed | 1,111 | RCT, Double-blind | LY450139, Placebo |
| NCT01435616 A Study in Patients With Type 2 Diabetes Mellitus | Diabetes Mellitus, Type 2 | P3 | Completed | 1,538 | RCT, Double-blind | Glargine, LY2605541 |
| NCT04250337 Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis. | Atopic Dermatitis | P3 | Completed | 228 | RCT, Double-blind | Lebrikizumab |
| NCT06584916 A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN) | Obesity, Overweight | P3 | Completed | 376 | RCT, Double-blind | Orforglipron, Placebo |
| NCT00996658 Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone | Diabetes Mellitus, Type 2 | P3 | Completed | 278 | RCT, Double-blind | Placebo, Linagliptin |
| NCT04537923 A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin | Type 2 Diabetes | P3 | Completed | 1,428 | RCT, Open-label | Tirzepatide, Insulin Lispro (U100) |
| NCT00191126 Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Gemcitabine-Cisplatin in Early Stages NSCLC | Non-Small Cell Lung Cancer | P3 | Completed | 263 | RCT, Open-label | gemcitabine, Cisplatin |
| NCT05780268 LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) | COVID-19 | P3 | Completed | 314 | RCT, Double-blind | LY3819253, Placebo, Remdesivir |
| NCT00568685 Atomoxetine to Treat Korean Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) | Attention Deficit Hyperactivity Disorder | P3 | Completed | 153 | RCT, Open-label | Atomoxetine Hydrochloride, Atomoxetine hydrochloride, Atomoxetine hydrochloride |
| NCT00560417 Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide | Diabetes Mellitus, Type 2 | P3 | Completed | 339 | RCT, Open-label | Insulin Lispro Protamine Suspension, Insulin Glargine |
| NCT02923921 Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer | Pancreatic Cancer | P3 | Completed | 567 | RCT, Open-label | Pegilodecakin, FOLFOX |
| NCT00676338 Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4) | Type 2 Diabetes Mellitus | P3 | Completed | 820 | RCT, Double-blind | exenatide once weekly, metformin, sitagliptin, pioglitazone |
| NCT00568737 The Study of Drotrecogin Alfa (Activated) in Adult Patients With Severe Sepsis at a Low Risk of Death | Sepsis | P3 | Completed | 2,640 | RCT, Double-blind | Drotrecogin alfa (activated), Placebo |
| NCT03057951 EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved) | Heart Failure | P3 | Completed | 5,988 | RCT, Double-blind | Empagliflozin, Placebo |
| NCT01997411 Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes | Diabetes Mellitus, Type 1 | P2P3 | Completed | 48 | RCT, Double-blind | Nasal Glucagon, Intramuscular Glucagon |
| NCT04591626 A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes | Type 2 Diabetes Mellitus | P3 | Completed | 291 | RCT, Double-blind | Dulaglutide, Placebo, Insulin Glargine |
| NCT01075282 A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2) | Diabetes Mellitus, Type 2 | P3 | Completed | 810 | RCT, Open-label | Insulin Glargine, LY2189265, Metformin, Glimepiride |
| NCT05024032 A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN) | Obesity, Overweight | P3 | Completed | 210 | RCT, Double-blind | Tirzepatide, Placebo |
| NCT00191152 A Phase III Trial For Patients With Metastatic Breast Cancer | Breast Cancer, Breast Neoplasms | P3 | Completed | 475 | RCT, Open-label | gemcitabine, docetaxel, capecitabine |
| NCT00489073 Duloxetine Versus Placebo for Fibromyalgia | Fibromyalgia | P3 | Completed | 345 | RCT, Double-blind | duloxetine, placebo |
| NCT03334396 A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis | Atopic Dermatitis | P3 | Completed | 660 | RCT, Double-blind | Baricitinib, Placebo |
| NCT00543218 PTH Comparison in Post Menopausal Women | Osteoporosis, Post-Menopausal | P3 | Completed | 63 | RCT, Open-label | teriparatide 20 micrograms/day subcutaneous, calcitonin 100 IU/day subcutaneous |
| NCT01005680 A Study Comparing Two Different Chemotherapy Types in Chinese Patients With Advanced Non Small Cell Lung Cancer | Non Small Cell Lung Cancer | P3 | Completed | 256 | RCT, Open-label | Pemetrexed, Gemcitabine, Cisplatin |
| NCT00191880 Open-Label Trial of Atomoxetine to Evaluate Academic Outcome in Children Ages 8-11 Years With Attention Deficit/Hyperactivity Disorder | Attention Deficit Hyperactivity Disorder | P3 | Completed | 100 | Open-label | atomoxetine |
| NCT00920582 Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus | Type 1 Diabetes Mellitus | P3 | Terminated | 254 | RCT, Double-blind | Teplizumab Herold Regimen, Placebo, Teplizumab 33.3% Herold Regimen, Teplizumab Curtailed Herold Regimen |
| NCT00577824 Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s) | Type 2 Diabetes | P3 | Completed | 181 | RCT, Double-blind | exenatide, exenatide, placebo |
| NCT00638638 Myocardial Infarction With ST-Elevation | Myocardial Infarction | P3 | Unknown | 292 | RCT, Double-blind | Abciximab, Abciximab placebo |
| NCT01003184 Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes | Type 2 Diabetes Mellitus | P3 | Completed | 222 | RCT, Open-label | exenatide once weekly, insulin detemir |
| NCT00391209 Compare Two Dosing Algorithms in Insulin-Naive Patients With Type 2 Diabetes Mellitus | Diabetes Mellitus, Type 2 | P3 | Completed | 379 | RCT, Open-label | simplified diabetes regimen starting with a fixed dose of Human Insulin Inhalation Powder, intensive diabetes management starting with an adjusted dose of Human Insulin Inhalation Powder |
| NCT00785421 Chemotherapy With or Without Enoxaparin in Pancreatic Cancer | Pancreatic Cancer | P2P3 | Completed | 312 | RCT, Open-label | enoxaparin, chemotherapy with LMWH - enoxaparin, only chemotherapy |
| NCT00146276 Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer | Bladder Cancer, Carcinoma, Transitional Cell | P3 | Unknown | 178 | RCT, Open-label | gemcitabine |
| NCT04517253 A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGS | Nakajo-Nishimura Syndrome, Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature Syndrome | P2P3 | Terminated | 10 | Open-label | Baricitinib |
| NCT01198002 A Rheumatoid Arthritis Study in Participants on a Background Treatment of Methotrexate | Rheumatoid Arthritis | P3 | Terminated | 1,041 | RCT, Double-blind | LY2127399, Placebo Q2W, Placebo Q4W, Methotrexate |
| NCT01202773 A Study in Participants With Rheumatoid Arthritis | Rheumatoid Arthritis | P3 | Terminated | 456 | RCT, Double-blind | LY2127399, Placebo Q4W, Placebo Q2W |
| NCT02008318 A Study of Galunisertib in Participants With Myelodysplastic Syndromes | Myelodysplastic Syndromes | P2P3 | Completed | 43 | Open-label | Galunisertib, Placebo |
| NCT00034268 A Phase 3 Trial of LY900003 Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer | Carcinoma, Non-Small-Cell Lung | P3 | Completed | — | RCT, Open-label | LY900003 |
| NCT01159600 Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes | Diabetes Mellitus, Type 2 | P3 | Completed | 1,504 | RCT, Double-blind | Placebo identical to BI 10773 high dose, Placebo identical to BI 10773 low dose, BI 10773, BI 10773, Placebo identical to BI 10773 low dose, BI 10773, Placebo identical to BI 10773 high dose |
| NCT00577863 Study of the Experience of Patients With Osteoporosis Using the Forteo B Pen to Self Administer Once Daily Teriparatide Therapy | Osteoporosis | P3 | Completed | 200 | Open-label | teriparatide |
| NCT01164501 Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment | Diabetes Mellitus, Type 2, Renal Insufficiency | P3 | Completed | 741 | RCT, Double-blind | BI 10773, Placebo, Placebo, BI 10773, Placebo, Placebo |
| NCT00279175 REPAIR-AMI: Intracoronary Progenitor Cells in Acute Myocardial Infarction (AMI) | Myocardial Infarction | P3 | Completed | 204 | RCT, Double-blind | Intracoronary infusion of enriched bone marrow-derived progenitor cells, Placebo medium supplemented with autologous serum |
| NCT00126139 Abciximab for Prevention of Stroke Recurrence Before Endarterectomy in Symptomatic Carotid Stenosis | Stroke, Stenosis | P3 | Terminated | 100 | RCT, Double-blind | Abciximab |
| NCT00552175 A Study for the Treatment of Diabetic Peripheral Neuropathic Pain | Diabetic Neuropathies | P3 | Completed | 339 | RCT, Double-blind | Duloxetine hydrochloride - 40 mg, placebo, Duloxetine hydrochloride - 60 mg |
| NCT03535194 A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2) | Psoriasis | P3 | Completed | 1,484 | RCT, Double-blind | Mirikizumab, Placebo, Secukinumab |
| NCT04285229 A Study of Ixekizumab (LY2439821) in Chinese Participants With Radiographic Axial Spondyloarthritis | Spondyloarthritis | P3 | Completed | 147 | RCT, Double-blind | Ixekizumab, Placebo |
| NCT00989157 Effects of Gastric Bypass on Blood Levels of Duloxetine | Bariatric Surgery | P3 | Completed | 20 | Open-label | Duloxetine |
| NCT00383422 Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis | Osteoporosis, Postmenopausal | P3 | Completed | 320 | RCT, Double-blind | Arzoxifene, Raloxifene |
| NCT00485901 Comparison of Intramuscular Olanzapine and Intramuscular Haloperidol in Patients With Schizophrenia | Schizophrenia | P3 | Completed | 50 | RCT, Double-blind | Olanzapine Hydrochloride, Haloperidol |
| NCT00384930 Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia | Benign Prostatic Hyperplasia | P2P3 | Completed | 1,058 | RCT, Double-blind | tadalafil, tadalafil, tadalafil, tadalafil, placebo |
| NCT01087502 Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment | Diabetes Mellitus, Type 2 | P3 | Completed | 241 | RCT, Double-blind | Glimepiride, Placebo, Placebo, Placebo, Linagliptin |
| NCT00568672 Optimal Duration of Olanzapine Add-on Therapy in Major Depression | Relapse Rate of a Major Depressive Episode, Safety of Olanzapine in Subjects With Major Depression | P3 | Withdrawn | — | RCT, Double-blind | Olanzapine |
| NCT00191100 Comparative Study of Gemcitabine,Cisplatin and Radiation Versus Cisplatin and Radiation in Cancer of the Cervix | Cancer of Cervix | P3 | Completed | 515 | RCT, Open-label | Gemcitabine, Cisplatin |
| NCT01794000 A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD) | Sickle Cell Disease | P3 | Terminated | 341 | RCT, Double-blind | Prasugrel, Placebo |
| NCT01937871 A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED) | Benign Prostate Hyperplasia, Erectile Dysfunction | P3 | Completed | 909 | RCT, Double-blind | 5 mg Tadalafil, Placebo, 0.2 mg Tamsulosin |
| NCT07881432 A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes | Obesity | P3 | Not Yet Recruiting | 2,115 | RCT, Double-blind | eloralintide and tirzepatide, Eloralintide, Tirzepatide, Placebo |
| NCT00827242 Study to Treat Patients Who Have Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) With Tadalafil Daily | Benign Prostatic Hyperplasia | P3 | Completed | 325 | RCT, Double-blind | Placebo, tadalafil |
| NCT01289990 Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes | Diabetes Mellitus, Type 2 | P3 | Completed | 2,705 | Double-blind | BI 10773, Placebo, Placebo, Placebo, Placebo, Placebo, BI 10773, Placebo, Placebo, BI 10773, Placebo, Placebo, Placebo, BI 10773, BI 10773, BI 10773, Placebo, BI 10773, Placebo, Placebo, Placebo, Sitagliptin 100mg, BI 10773, Placebo, Placebo, Placebo, Placebo, Placebo, Placebo, Placebo |
| NCT03421379 A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus | Diabetes Mellitus | P3 | Completed | 75 | RCT, Open-label | Glucagon Nasal Powder, Glucagon Hydrochloride Solution |
| NCT00121446 Which Therapy for Acute Heart Attacks? (The WEST Study) | Myocardial Infarction | P2P3 | Completed | 300 | RCT, Open-label | tenecteplase, enoxaparin, clopidogrel |
| NCT05074420 A Study of Baricitinib (LY3009104) in Children With COVID-19 | Covid19, Corona Virus Infection | P3 | Terminated | 6 | Open-label | Baricitinib |
| NCT00547183 Study the Safety and Effectiveness of Tadalafil in Men With Diabetes Who Have Problems Getting and Keeping an Erection | Impotence | P3 | Completed | 298 | RCT, Double-blind | tadalafil, tadalafil, placebo |
| NCT04421027 A Study of Baricitinib (LY3009104) in Participants With COVID-19 | COVID-19 | P3 | Completed | 1,525 | RCT, Double-blind | Baricitinib, Placebo |
| NCT01185340 A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor | Major Depressive Disorder | P3 | Completed | 1,056 | RCT, Double-blind | LY2216684, Placebo, SSRI |
| NCT06010004 A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes | Type 2 Diabetes | P3 | Completed | 401 | RCT, Open-label | Orforglipron |
| NCT03861039 A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes | Type 2 Diabetes Mellitus | P3 | Completed | 443 | RCT, Open-label | Tirzepatide, Oral antihyperglycemic medication (OAM) |
| NCT04250350 Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis | Atopic Dermatitis | P3 | Completed | 206 | Open-label | Lebrikizumab |
| NCT00747968 The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PET | Type 2 Diabetes | P2P3 | Completed | 8 | RCT, Double-blind | Byetta, Exenatide |
| NCT00485550 Comparison of Atomoxetine Plus Either Comparator or Placebo in Children With ADHD Who Haven't Responded to Stimulant Therapy | Attention Deficit Hyperactivity Disorder | P3 | Completed | 14 | RCT, Double-blind | Atomoxetine Hydrochloride, Methylphenidate Hydrochloride, Placebo |
| NCT00734474 A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin | Diabetes Mellitus, Type 2 | P2P3 | Completed | 1,202 | RCT, Double-blind | LY2189265, Sitagliptin, Placebo solution, Placebo tablet, Metformin |
| NCT00190710 A Trial of Carboplatin and Gemcitabine Versus Gemcitabine Alone in Patients With Non-Small-Cell Lung Cancer | Non-Small Cell Lung Cancer | P3 | Completed | 242 | RCT, Open-label | Gemcitabine, Carboplatin |
| NCT01131676 BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME). | Diabetes Mellitus, Type 2 | P3 | Completed | 7,064 | RCT, Double-blind | BI 10773 low dose, Placebo BI 10773 high dose, BI 10773 high dose, Placebo BI 10773 low dose, Placebo BI 10773 low dose, Placebo BI 10773 high dose |
| NCT01205438 A Study of LY2127399 in Participants With Systemic Lupus Erythematosus | Systemic Lupus Erythematosus, Connective Tissue Disease | P3 | Completed | 1,124 | RCT, Double-blind | LY2127399, Placebo every 2 weeks, Placebo every 4 weeks |
| NCT01422876 Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients | Diabetes Mellitus, Type 2 | P3 | Completed | 1,405 | RCT, Double-blind | high dose FDC, BI 10773 high dose, high dose FDC placebo, low dose FDC placebo, high dose FDC placebo, high dose FDC placebo, low dose FDC placebo, low dose FDC placebo, high dose BI 10773 placebo, low dose FDC, high dose FDC placebo, BI 10773 low dose, high dose BI 10773 placebo, high dose BI 10773 placebo, linagliptin, low dose FDC placebo, linagliptin placebo, BI 10773 low dose placebo, linagliptin placebo, low dose BI 10773 placebo, linagliptin placebo, high dose BI 10773 placebo, BI 10773 low dose placebo, low dose BI 10773 placebo, linagliptin placebo |
| NCT03952143 A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes | Type 2 Diabetes Mellitus | P3 | Completed | 628 | RCT, Double-blind | LY900014, Insulin Lispro, Insulin Glargine, Insulin Degludec |
| NCT02453555 Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus | Diabetes Mellitus, Type 2 | P3 | Completed | 275 | RCT, Double-blind | Linagliptin, Empagliflozin placebo + linagliptin placebo low dose, Empagliflozin + linagliptin low dose, Linagliptin placebo, Empagliflozin + linagliptin high dose, Empa + lina highdose placebo |
| NCT00122824 Duloxetine Compared With Placebo in Patients With Generalized Anxiety Disorder | Anxiety Disorders | P3 | Completed | 480 | RCT, Double-blind | duloxetine hydrochloride, placebo |
| NCT00917267 A Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control and Safety in Asian Subjects | Type 2 Diabetes Mellitus | P3 | Completed | 691 | RCT, Open-label | exenatide once weekly, exenatide twice daily |
| NCT00077233 FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum | Colorectal Cancer | P3 | Terminated | 238 | RCT, Open-label | cetuximab, 5-FU, irinotecan, leucovorin, oxaliplatin |
| NCT03670810 A Study of Lasmiditan (LY573144) Over Four Migraine Attacks | Migraine | P3 | Completed | 1,633 | RCT, Double-blind | Lasmiditan, Placebo |
| NCT00051298 Olanzapine Versus Placebo in the Treatment of Adolescents With Schizophrenia | Schizophrenia | P3 | Completed | 107 | RCT, Double-blind | Olanzapine, Placebo |
| NCT01167023 Prasugrel Versus Placebo in Adult Sickle Cell Disease | Sickle Cell Anemia | P2 | Completed | 62 | RCT, Double-blind | Prasugrel, Placebo |
| NCT00103935 Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes | Type 2 Diabetes Mellitus | P2 | Completed | 45 | RCT, Double-blind | placebo, placebo, Exenatide LAR, Exenatide LAR |
| NCT00384774 A Placebo-Controlled Adaptive Treatment Assignment Study of Intravenous COL-144 in the Acute Treatment of Migraine | Migraine | P2 | Completed | 130 | RCT, Double-blind | Lasmiditan, Placebo |
| NCT00202800 Phase II Trial to Evaluate Gemcitabine and Etoposide for Locally Advanced or Metastatic Pancreatic Cancer | Pancreatic Cancer | P2 | Completed | 40 | Single-blind | Gemcitabine, Etoposide |
| NCT01774981 Study of LY3016859 in Participants With Diabetic Nephropathy | Diabetic Nephropathy | P1P2 | Completed | 60 | RCT, Double-blind | Placebo, LY3016859 |
| NCT04493502 A Study of LY3041658 in Adults With Hidradenitis Suppurativa | Hidradenitis Suppurativa | P2 | Completed | 72 | RCT, Double-blind | Placebo, LY3041658 |
| NCT04640077 A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT) | Alzheimer Disease, Dementia | P2 | Completed | 95 | Open-label | donanemab |
| NCT06074562 A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain | Diabetic Peripheral Neuropathy | P2 | Completed | 404 | RCT, Double-blind | Mazisotine, Placebo |
| NCT00409006 Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers | Non-small Cell Lung Cancer | P2 | Completed | 70 | RCT, Open-label | Pemetrexed, Cisplatin, Gefitinib |
| NCT00149214 Preoperative Treatment of Breast Cancer With Two Different Sequential Treatment Regimens | Breast Cancer | P2 | Completed | 257 | RCT, Open-label | pemetrexed, cyclophosphamide, doxorubicin, docetaxel |
| NCT01408095 A Study in Patients With Type 2 Diabetes | Diabetes Mellitus, Type 2 | P2 | Withdrawn | 240 | RCT, Double-blind | LY2608204, Glimepiride |
| NCT00192075 A Randomized Trial of Avastin + Gemcitabine + 5-Fluorouracil (5FU)/Folinic Acid Versus Avastin + Oxaliplatin + 5FU/Folinic Acid in Metastatic Colorectal Cancer | Colorectal Cancer | P2 | Completed | 84 | RCT, Open-label | Gemcitabine, avastin, 5FU/folinic acid, oxaliplatin |
| NCT00383292 A Study of Tasisulam in Treating Participants With Malignant Melanoma | Metastatic Melanoma | P2 | Completed | 130 | Open-label | tasisulam |
| NCT00370292 Dosage Schedule Study of Pemetrexed Monochemotherapy for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer | P2 | Completed | 19 | Open-label | Pemetrexed - Before Protocol Amendment, Pemetrexed - After Protocol Amendment |
| NCT01113801 A Study in Participants With Diabetic Kidney Disease | Diabetic Kidney Disease, Diabetic Nephropathy | P2 | Terminated | 417 | RCT, Double-blind | LY2382770, Placebo |
| NCT00201760 Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer | Breast Cancer | P2 | Completed | 10 | RCT, Open-label | Gemcitabine, Trastuzumab, Cisplatin |
| NCT00280150 Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer | Lung Cancer | P1P2 | Completed | 46 | Open-label | bevacizumab, carboplatin, erlotinib hydrochloride, paclitaxel |
| NCT04585776 A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes | Type 1 Diabetes | P2 | Completed | 31 | Open-label | LY900014, Insulin Degludec |
| NCT05256654 A Study of LY3561774 in Participants With Mixed Dyslipidemia | Dyslipidemias, Lipid Metabolism Disorders | P2 | Completed | 205 | RCT, Double-blind | LY3561774, Placebo |
| NCT00063388 Phase II Study in Patients With Recurrent Non-Small-Cell Lung Cancer | Non-Small-Cell Lung Cancer | P2 | Completed | 66 | Open-label | Cetuximab |
| NCT00215930 The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer | Carcinoma, Non-Small-Cell Lung | P2 | Completed | 53 | Open-label | Vinorelbine, Docetaxel, Gemcitabine, Carboplatin |
| NCT00102219 A Study of Pemetrexed Plus Doxorubicin Given to Patients With Advanced Breast Cancer | Breast Cancer | P2 | Completed | 77 | Open-label | Pemetrexed, Doxorubicin |
| NCT00538681 Study for Participants With Advanced, Not Amenable to Surgery, or Metastatic Lung Cancer Comparing Treatment With Pemetrexed + Cisplatin + Enzastaurin Versus Pemetrexed + Cisplatin + Placebo | Lung Cancer | P2 | Terminated | 35 | RCT, Double-blind | enzastaurin, pemetrexed, cisplatin, placebo |
| NCT05611671 A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC | Inflammatory Bowel Diseases, Colitis, Ulcerative | P2 | Completed | 280 | RCT, Double-blind | MORF-057, Placebo |
| NCT00527111 Pre-op Rectal ChemoRad +/- Cetuximab | Rectal Cancer | P2 | Completed | 139 | RCT, Open-label | Cetuximab, 5-fluorouracil |
| NCT00450762 Gemcitabine + Carboplatin in Breast Cancer | Breast Cancer | P2 | Completed | — | Open-label | gemcitabine, carboplatin |
| NCT01763788 A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) | Squamous Non-small Cell Lung Cancer | P1P2 | Completed | 192 | RCT, Open-label | Necitumumab, Gemcitabine, Cisplatin |
| NCT00456261 First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC | Lung Cancer | P2 | Completed | 110 | RCT, Open-label | Pemetrexed, Gemcitabine, Bevacizumab, Carboplatin |
| NCT00191373 A Trial for HER2 Positive Breast Cancer Patients With Metastatic Disease | Breast Neoplasms, Cancer of the Breast | P2 | Completed | 66 | Open-label | Gemcitabine, Trastuzumab |
| NCT00913835 A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer | Ovarian Neoplasms | P2 | Completed | 125 | RCT, Open-label | Olaratumab, liposomal doxorubicin |
| NCT00466440 A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients | Prostate Cancer | P2 | Completed | 108 | RCT, Double-blind | enzastaurin, placebo, docetaxel, prednisone |
| NCT00617201 Evaluation of Atomoxetine for Cocaine Dependence: A Pilot Trial | Substance Abuse | P2 | Completed | 50 | RCT, Double-blind | atomoxetine, placebo |
| NCT01193218 Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus | Diabetes Mellitus, Type 2 | P2 | Completed | 547 | RCT, Double-blind | Placebo (low dose), Placebo (low dose), Placebo (mid dose), Placebo (high dose), BI 10773, Placebo (mid dose), Placebo (high dose), Placebo (high dose), BI 10773, BI 10773, Placebo (mid dose), Placebo (high dose), Placebo (low dose), Placebo (low dose), BI 10773, Placebo (mid dose) |
| NCT03137160 An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum | Pyoderma Gangrenosum | P2 | Completed | 4 | Open-label | Ixekizumab |
| NCT00190671 A Study of Pemetrexed and Cyclophosphamide Given Every 21 Days in Advanced Breast Cancer Patients | Breast Cancer | P1P2 | Completed | 103 | RCT, Open-label | pemetrexed, cyclophosphamide, pemetrexed |
| NCT01027871 A Study for Patients With Type 2 Diabetes | Diabetes Mellitus, Type 2 | P2 | Completed | 289 | RCT, Open-label | LY2605541, insulin glargine |
| NCT01107444 Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer | Non-small Cell Lung Cancer | P2 | Completed | 180 | RCT, Open-label | Docetaxel, LY2181308 |
| NCT00759772 The Role of Parathyroid Hormone (PTH) in Low Bone Mass in Anorexia Nervosa | Anorexia Nervosa, Osteoporosis | P2 | Completed | 23 | RCT, Single-blind | Placebo, Teriparatide |
| NCT00116519 A Study in People With Abnormal Fat Levels in the Blood | Dyslipidemia | P2 | Completed | 300 | RCT, Double-blind | PPAR alpha, placebo |
| NCT00115635 Docetaxel and Gemcitabine in Hormonal Refractory Metastatic Prostate Cancer | Prostate Cancer | P1P2 | Completed | 60 | Open-label | docetaxel, gemcitabine |
| NCT02659020 A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma | Soft Tissue Sarcoma | P1P2 | Completed | 310 | RCT, Double-blind | Olaratumab, Gemcitabine, Docetaxel, Placebo |
| NCT00515697 A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma | P2 | Completed | 39 | Open-label | Ramucirumab |
| NCT00316238 A Study Using Rapid Acting Intramuscular Olanzapine in Agitated Patients With Schizophrenia | Schizophrenia | P2 | Completed | 160 | RCT, Double-blind | olanzapine-RAIM, placebo |
| NCT00332553 Study of Hot Flashes and Night Sweats in Postmenopausal Women Receiving Combination Raloxifene and Oral Estrogen | Vasomotor Symptoms, Endometrial Safety | P2 | Completed | 150 | RCT, Double-blind | Raloxifene, medroxyprogesterone acetate, estrogen, 17 beta estradiol |
| NCT00768131 A Study to Determine Whether EGFR Status by FISH Can Predict Results in Non Small Cell Lung Cancer (NSCLC) Patients Treated With Cetuximab, Carboplatin and Paclitaxel | Lung Neoplasms, Carcinoma, Non-Small-Cell Lung | P2 | Withdrawn | — | RCT, Open-label | Cetuximab, Paclitaxel, Carboplatin |
| NCT04158700 A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer | Advanced Cancer | P1P2 | Withdrawn | — | Open-label | LY3200882, Pembrolizumab |
| NCT00533429 Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Participants With Non-Small Cell Lung Cancer Who Have Not Been Previously Treated With Chemotherapy | Non-small Cell Lung Cancer | P2 | Completed | 40 | RCT, Double-blind | enzastaurin, pemetrexed, carboplatin, bevacizumab, Placebo |
| NCT00106002 Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer | Breast Cancer, Breast Neoplasms, Male | P2 | Completed | 37 | Open-label | pemetrexed |
| NCT00418093 Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma | Ovarian Cancer, Fallopian Tube Cancer | P2 | Terminated | 19 | Open-label | Gemcitabine, Oxaliplatin, Bevacizumab |
| NCT02102490 A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread | Metastatic Breast Cancer | P2 | Completed | 132 | Open-label | Abemaciclib |
| NCT00523640 A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma | Carcinoma, Renal Cell | P2 | Terminated | 30 | Open-label | combination of gemcitabine, capecitabine, and bevacizumab |
| NCT01703091 A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | P2 | Completed | 197 | RCT, Double-blind | Ramucirumab, Placebo, Docetaxel |
| NCT00259285 Pemetrexed and Cisplatin Treatment Before Surgery in Non Small Cell Lung Cancer | Non-Small-Cell Lung Cancer | P2 | Terminated | 10 | Open-label | pemetrexed, cisplatin |
| NCT00862784 A Study of IMC-1121B (Ramucirumab) in Colorectal Cancer | Colorectal Carcinoma | P2 | Completed | 48 | Open-label | IMC-1121B (ramucirumab), Oxaliplatin, Folinic acid, 5-FU, 5-FU |
| NCT02431052 A Dose-ranging Study of DRM01 in Subjects With Acne Vulgaris | Acne Vulgaris | P2 | Completed | 420 | RCT, Double-blind | Olumacostat Glasaretil |
| NCT00034593 A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium | Urologic Neoplasms | P2 | Completed | — | — | ALIMTA, gemcitabine |
| NCT00216164 Rituximab and Gemcitabine for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Lymphoma, B-Cell | P2 | Terminated | 8 | Open-label | Rituximab, Gemcitabine |
| NCT05080660 Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Osteoarthritis | Osteoarthritis, Osteo Arthritis Knee | P2 | Completed | 160 | RCT, Double-blind | LY3526318, Placebo |
| NCT01011868 Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes | Diabetes Mellitus, Type 2 | P2 | Completed | 494 | RCT, Double-blind | BI 10773 placebo, BI 10773 low dose, BI 10773 high dose, BI 10773 placebo |
| NCT00906282 Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer | Non Small Cell Lung Cancer | P2 | Completed | 46 | Open-label | Pemetrexed, Carboplatin |
| NCT03370276 Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma | Squamous Cell Carcinoma of the Oropharynx, Squamous Cell Carcinoma of the Larynx | P1P2 | Completed | 95 | Open-label | Nivolumab, Cetuximab |
| NCT07548450 Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER) | Waldenstrom Macroglobulinemia | P2 | Not Yet Recruiting | 25 | Open-label | Pirtobrutinib, Mosunetuzumab |
| NCT02981342 A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | P2 | Completed | 106 | RCT, Open-label | Abemaciclib, LY3023414, Gemcitabine, Capecitabine |
| NCT03831191 A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis | Atopic Dermatitis | P2 | Terminated | 136 | RCT, Double-blind | LY3375880, Placebo |
| NCT00721162 Study of Ramucirumab in Ovarian Cancer | Ovarian Cancer, Fallopian Tube Cancer | P2 | Completed | 60 | Open-label | Ramucirumab |
| NCT00400803 Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer | Carcinoma, Non-Small-Cell Lung | P2 | Completed | 38 | Open-label | Gemcitabine, Carboplatin, Bevacizumab |
| NCT00051909 Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease | Alzheimer's Disease | P2 | Completed | 200 | RCT, Double-blind | LY451395 |
| NCT00368849 Atomoxetine and Huntington's Disease | Huntington Disease, Chorea | P2 | Completed | 20 | RCT, Double-blind | atomoxetine, Matching Placebo |
| NCT00529204 Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease | Diabetes Complications, Fatty Liver | P2 | Terminated | 1 | Open-label | exenatide |
| NCT01025284 A Study for Participants With Small-Cell Lung Cancer | Small Cell Lung Cancer | P2 | Completed | 64 | Open-label | LY2523355, Granulocyte colony-stimulating factor (G-CSF) |
| NCT00061464 Pemetrexed Plus Gemcitabine for Patients With Locally Advanced or Metastatic NSCLC Who Have Not Had Previous Chemotherapy. | Carcinoma, Non-Small-Cell Lung | P2 | Completed | 48 | Open-label | pemetrexed, gemcitabine |
| NCT00192114 Enzastaurin for Patients With Metastatic Colorectal Cancer | Colonic Neoplasms | P2 | Completed | 28 | Open-label | Enzastaurin HCl |
| NCT05063539 A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease | Alzheimer Disease | P2 | Completed | 327 | RCT, Double-blind | LY3372689, LY3372689, Placebo |
| NCT00402883 Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer | Lung Cancer | P2 | Terminated | 5 | Open-label | Bevacizumab, Pemetrexed, carboplatin |
| NCT00540124 Pilot Study Investigating Safety and Efficacy of Tadalafil as Treatment for Benign Prostatic Hyperplasia (BPH) in Asian Men | Benign Prostatic Hyperplasia | P2 | Completed | 151 | RCT, Double-blind | Tadalafil, Placebo, Tamsulosin |
| NCT00942188 A Study of LY2189102 in Patients With Type 2 Diabetes | Type 2 Diabetes | P2 | Completed | 106 | RCT, Double-blind | LY2189102, Placebo |
| NCT01160744 A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC) | Carcinoma, Non-Small-Cell Lung | P2 | Completed | 280 | RCT, Open-label | IMC-1121B (ramucirumab), Pemetrexed, Carboplatin (AUC 6), Cisplatin, Gemcitabine, Carboplatin (AUC 5) |
| NCT00966875 A Study in Patients With Rheumatoid Arthritis | Rheumatoid Arthritis | P2 | Completed | 448 | RCT, Double-blind | LY2439821, Placebo |
| NCT00063128 Safety and Efficacy of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes Mellitus. | Diabetes Mellitus, Type 1 | P2 | Completed | 119 | RCT, Open-label | insulin, human insulin inhalation powder (HIIP) |
| NCT00491075 Pemetrexed Plus Gemcitabine in Renal Cell Cancer | Renal Cell Carcinoma | P2 | Terminated | 16 | Open-label | Pemetrexed, Gemcitabine |
| NCT00950365 Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer | Bronchioloalveolar Carcinoma, Large Cell Lung Carcinoma | P2 | Completed | 79 | RCT, Open-label | Erlotinib Hydrochloride, Pemetrexed Disodium |
| NCT00222729 Study of Pemetrexed and Bevacizumab in Patients With Head and Neck Cancer | Cancer | P2 | Completed | 42 | Open-label | Pemetrexed, Bevacizumab |
| NCT00957853 Preoperative Treatment With Cetuximab and/or IMC-A12 | Head and Neck Squamous Cell Carcinoma | P2 | Completed | 16 | RCT, Open-label | Cetuximab, IMC-A12 |
| NCT00034541 Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer | Carcinoma, Non-Small-Cell Lung | P1P2 | Completed | 32 | Open-label | cetuximab, paclitaxel, carboplatin |
| NCT03086369 A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer | Metastatic Pancreatic Cancer | P1P2 | Completed | 184 | RCT, Double-blind | Olaratumab, Nab-paclitaxel, Gemcitabine, Placebo |
| NCT01029795 A Study of LY2599506 (Oral Agent Medication: Glucokinase Activator 1) in Type 2 Diabetes Mellitus | Diabetes Mellitus, Type 2 | P2 | Terminated | 38 | RCT, Double-blind | LY2599506, Glyburide, Placebo |
| NCT00542919 A Study for Patients With Non-Hodgkin's Lymphomas | T-Cell Lymphoma, B-Cell Lymphoma | P2 | Completed | 57 | Open-label | enzastaurin |
| NCT00061451 Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Clinical Trial | Carcinoma, Non-Small-Cell Lung | P2 | Completed | 48 | Open-label | Pemetrexed, Gemcitabine |
| NCT06124807 A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight | Obesity, Overweight and Obesity | P2 | Completed | 179 | RCT, Double-blind | Mazdutide, Placebo |
| NCT01001104 A Study of LY2189265 in Japanese Patients With Type 2 Diabetes | Diabetes Mellitus, Type 2 | P2 | Completed | 145 | RCT, Double-blind | LY2189265, Placebo |
| NCT00099333 Study of the Safety of Substituting Exenatide for Insulin in Patients Using Insulin and Oral Antidiabetic Agents | Type 2 Diabetes Mellitus | P2 | Completed | 49 | RCT, Open-label | exenatide, Insulin |
| NCT00191984 A Study of the Combination of Pemetrexed and Irinotecan Every Two Weeks in Metastatic Colorectal Cancer | Metastatic Colorectal Cancer | P2 | Completed | 46 | Open-label | pemetrexed, irinotecan |
| NCT04032080 LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer | Triple Negative Breast Cancer | P2 | Completed | 10 | Open-label | — |
| NCT02443883 A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer | Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | P2 | Completed | 164 | RCT, Open-label | Ramucirumab |
| NCT04417361 Galcanezumab for Vestibular Migraine | Vestibular Migraine | P2 | Completed | 40 | RCT, Double-blind | Galcanezumab Prefilled Syringe, Placebo |
| NCT00455442 A Two-Week Study of the Efficacy and Safety of Mifepristone in the Prevention of Olanzapine-Induced Weight Gain | Weight-Gain Prevention | P2 | Completed | 57 | RCT, Double-blind | Mifepristone |
| NCT03742973 A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA | Primary Biliary Cholangitis | P2 | Terminated | 2 | RCT, Double-blind | Baricitinib, Placebo |
| NCT00436280 Chemotherapy for Participants With Lymphoma | Lymphoma, Large Cell, Diffuse | P2 | Completed | 68 | Open-label | enzastaurin, gemcitabine, rituximab, oxaliplatin |
| NCT00112346 Study of Gemcitabine/Platinum +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer | Non-Small-Cell Lung Carcinoma | P2 | Completed | 120 | RCT, Open-label | Cetuximab + platinum + gemcitabine, Platinum + Gemcitabine |
| NCT01000480 A Study of Pemetrexed and Cisplatin, in Non Small Cell Lung Cancer | Non Small Cell Lung Cancer | P2 | Completed | 90 | Open-label | Pemetrexed, Cisplatin |
| NCT00804570 A Study for the Treatment of Alcohol Dependence | Alcohol Dependence | P2 | Completed | 375 | RCT, Double-blind | LY2196044, placebo |
| NCT05086289 Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Chronic Low Back Pain | Chronic Low-back Pain | P2 | Completed | 159 | RCT, Double-blind | LY3526318, Placebo |
| NCT00420004 A Study for Participants With Major Depression | Major Depressive Disorder | P2 | Completed | 469 | RCT, Double-blind | LY2216684, Placebo, Escitalopram |
| NCT07085468 A Study of LY3549492 in Healthy Weight Adult Participants | Healthy | P2 | Terminated | 1 | RCT, Double-blind | LY3549492, Placebo |
| NCT07030868 A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes | Obesity, Overweight | P2 | Terminated | 1 | RCT, Double-blind | LY3549492, Placebo |
| NCT00162110 A Trial of Erbitux for Recurrent and Metastatic Mucinous Gastrointestinal Adenocarcinoma Involving the Peritoneal Surfaces | Mucinous Gastrointestinal Adenocarcinoma | P2 | Completed | 40 | Open-label | cetuximab |
| NCT00609518 A Study for Patients With Non-Squamous Non-Small Cell Lung Cancer | Non Small Cell Lung Cancer | P2 | Completed | 111 | RCT, Open-label | pemetrexed, dexamethasone, dexamethasone |
| NCT00329082 Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers | Alzheimer's Disease | P2 | Completed | 25 | RCT, Double-blind | LY2062430, Placebo |
| NCT02791191 A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia | Alzheimer's Disease | P2 | Terminated | 316 | RCT, Double-blind | LY3202626, Placebo |
| NCT00451178 A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only | Lymphoma | P2 | Completed | 101 | RCT, Open-label | enzastaurin, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone |
| NCT03470350 Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer | Colorectal Cancer Metastatic | P1P2 | Withdrawn | — | Open-label | Galunisertib |
| NCT02443337 A Study of LY3023414 and Necitumumab in Squamous Lung Cancer | Non-small Cell Lung Cancer Metastatic | P2 | Terminated | 31 | Open-label | LY3023414, Necitumumab |
| NCT00623974 Teriparatide (Forteo) in the Treatment of Patients With Postoperative Hypocalcemia | Hypocalcemia | P2 | Terminated | 7 | RCT, Open-label | Teriparatide (Forteo), Calcium, Calcitriol |
| NCT04031872 LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615) | Colorectal Cancer Metastatic | P1P2 | Withdrawn | — | Open-label | LY3200882 |
| NCT00797472 Study Comparing R-mabHD and a Combination of ABVD in Hodgkin's Disease | Hodgkin's Disease | P2 | Unknown | 120 | RCT, Open-label | R-mabHD, ABVD |
| NCT06568042 Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy | Neuropathic Pain, Distal Sensory Polyneuropathy | P2 | Completed | 558 | RCT, Double-blind | LY3848575, Placebo |
| NCT00191308 Molecular Profiling in Lung Cancer Patients | Non-Small Cell Lung Cancer, Carcinoma | P2 | Completed | 30 | Open-label | pemetrexed, cisplatin |
| NCT04849416 A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia) | Leukemia, Lymphoid, Lymphoma, Non-Hodgkin | P2 | Completed | 87 | Open-label | LOXO-305 |
| NCT07920887 A Study of Bimagrumab in Participants With HFpEF | Heart Failure, Diastolic, Diastolic Heart Failure | P2 | Not Yet Recruiting | 540 | RCT, Double-blind | Bimagrumab, Placebo |
| NCT03764774 A Study of LY3463251 in Healthy Participants | Healthy | P1 | Terminated | 118 | RCT, Double-blind | LY3463251, Placebo |
| NCT01408888 A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes | Diabetes Mellitus, Type 2 | P1 | Completed | 29 | RCT, Open-label | LY2189265, Sitagliptin |
| NCT06690996 A Study of LY4005130 in Healthy Participants | Healthy | P1 | Completed | 110 | RCT, Double-blind | LY4005130, LY4005130, Placebo, Placebo |
| NCT01991483 A Study of LY2928057 in Hemodialysis Participants | Renal Insufficiency, Chronic, Kidney Disease, Chronic | P1 | Completed | 28 | RCT, Double-blind | LY2928057, Placebo |
| NCT06991179 A Study of Food Effect and Esomeprazole on LY4064809 in Healthy Adult Participants | Healthy | P1 | Completed | 36 | RCT, Open-label | LY4064809 |
| NCT05515601 A Bioequivalence Study of Mirikizumab (LY3074828) in Healthy Participants | Healthy | P1 | Completed | 396 | RCT, Single-blind | Mirikizumab |
| NCT05086445 A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus | Diabetes Mellitus, Type 2 | P1 | Completed | 62 | RCT, Double-blind | LY3502970, Placebo |
| NCT01275157 Disposition of 14C-LY2452473 Following Oral Administration in Healthy Human Subjects | Healthy Volunteers | P1 | Completed | 6 | Open-label | LY2452473 |
| NCT01736241 A Study of LY3053102 in Healthy Participants | Healthy Volunteers | P1 | Completed | 41 | RCT, Double-blind | LY3053102, Placebo |
| NCT06023095 A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities | Overweight, Obesity | P1 | Completed | 24 | RCT, Double-blind | LY3502970, Placebo |
| NCT03944031 A Study of the Effects of LY3372689 on the Brain in Healthy Participants | Healthy | P1 | Completed | 17 | Open-label | LY3372689 |
| NCT03341312 A Comparative Study of LY900014 With Insulin Lispro (Humalog) in Participants With Type 2 Diabetes Mellitus (T2DM) | Diabetes Mellitus, Type 2 | P1 | Completed | 36 | RCT, Double-blind | LY900014, Insulin Lispro |
| NCT01784614 A Study of LY2624803 in Japanese Participants With Transient Insomnia | Sleep Initiation and Maintenance Disorders | P1 | Completed | 24 | RCT, Double-blind | LY2624803 - Solution, LY2624803 - Capsule, Placebo - Solution, Placebo - Capsule |
| NCT00369629 Gemcitabine and Pemetrexed Disodium in Treating Patients With Advanced Mycosis Fungoides or Sézary Syndrome | Lymphoma | P1 | Terminated | 14 | Open-label | Gemcitabine, Pemetrexed |
| NCT02718911 A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors | Solid Tumor | P1 | Completed | 72 | Open-label | LY3022855, Durvalumab, Tremelimumab |
| NCT03406260 A Study of Lasmiditan in Healthy Elderly Participants | Healthy | P1 | Completed | 36 | RCT, Double-blind | Lasmiditan, Placebo |
| NCT02951780 A Study of LY3185643 and rGlucagon in Healthy Participants | Healthy | P1 | Completed | 23 | RCT, Double-blind | LY3185643, rGlucagon |
| NCT07439250 A Study of Olomorasib (LY3537982) in Healthy Participants | Healthy | P1 | Completed | 15 | Open-label | Olomorasib, Fluconazole |
| NCT04081324 A Study of Lasmiditan in Healthy Chinese Participants | Healthy | P1 | Completed | 36 | RCT, Double-blind | Lasmiditan, Placebo |
| NCT04071262 A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Therapies in Japanese Participants With Advanced Cancer | Advanced Cancer | P1 | Completed | 6 | Open-label | Abemaciclib, Abiraterone Acetate, Prednisolone |
| NCT06052462 A Study of Carbon-14-Labelled [14C] LY3556050 in Healthy Male Participants | Healthy | P1 | Completed | 7 | Open-label | [14C]-LY3556050 |
| NCT03495323 A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors | Cancer | P1 | Completed | 17 | Open-label | LY3300054, Prexasertib |
| NCT02588950 A Study of U-500 Insulin (LY041001) in Participants With Type 2 Diabetes | Diabetes Mellitus, Type 2 | P1 | Terminated | 11 | RCT, Open-label | U-500R |
| NCT04194892 A Crossover Study to Evaluate Pegilodecakin (LY3500518) in Healthy Participants | Healthy Adult Subjects | P1 | Completed | 12 | RCT, Open-label | Pegilodecakin |
| NCT05134337 Study of the Effects of Itraconazole and Rifampin on LOXO-305 in Healthy Participants | Healthy Volunteers | P1 | Completed | 27 | Open-label | LOXO-305, Itraconazole, Rifampin |
| NCT02317575 A Study of LY900014 Formulations in Healthy Participants | Healthy Volunteers | P1 | Completed | 29 | RCT, Double-blind | LY900014, Insulin Lispro |
| NCT02242981 A Study of How the Body Breaks Down and Eliminates LY2623091 | Healthy Volunteers | P1 | Completed | 6 | Open-label | LY2623091 |
| NCT00052273 LY317615 Plus Capecitabine in Treating Patients With Advanced Solid Tumors | Adult, Solid Tumor | P1 | Completed | 16 | — | capecitabine, enzastaurin hydrochloride |
| NCT01632566 A Multiple-dose Study of LY3031207 in Healthy Participants | Healthy Volunteers | P1 | Terminated | 39 | RCT, Double-blind | Placebo, LY3031207, Celecoxib, Simvastatin |
| NCT01695005 A Study of LY3039478 in Participants With Advanced Cancer | Neoplasms, Neoplasm Metastasis | P1 | Completed | 247 | Open-label | LY3039478, Prednisone |
| NCT07867340 A Study of Single and Multiple Doses of LY5625573 in Healthy Participants, Including Japanese and Chinese Populations, and Participants With Inflammation (High C-Reactive Protein) | C-Reactive Protein | P1 | Not Yet Recruiting | 96 | RCT, Double-blind | LY5625573, Midazolam, Placebo |
| NCT03977974 A Study of LY3526318 in Healthy Participants | Healthy | P1 | Terminated | 76 | RCT, Double-blind | LY3526318, Placebo |
| NCT04161976 A Study of LY900027 Given by Insulin Pump to Participants With Type 1 Diabetes Mellitus | Diabetes Mellitus, Type 1 | P1 | Completed | 20 | RCT, Double-blind | LY900027, Insulin Lispro |
| NCT01779830 A Study of LY2624803 in Participants With Transient Insomnia | Transient Insomnia | P1 | Completed | 32 | RCT, Double-blind | LY2624803 - Capsules, Zolpidem - Tablets, Placebo - Capsules, Placebo - Tablets |
| NCT06869018 A Study of LY3549492 in Japanese Participants With Type 2 Diabetes Mellitus (T2D) and Healthy Japanese Participants | Healthy, Type 2 Diabetes Mellitus (T2D) | P1 | Completed | 92 | RCT, Double-blind | LY3549492, Placebo |
| NCT03259490 This Study Tests Whether Taking the Medicines Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills. The Study is Done in Healthy Men and Women and Measures the Amount of Each Medicine in the Blood | Healthy | P1 | Completed | 30 | RCT, Open-label | Empagliflozin/linagliptin/metformin HCl, Empagliflozin, Linagliptin, Metformin HCl |
| NCT02123459 A Study of Cephalexin Suspension in Healthy Participants | Healthy Volunteers | P1 | Completed | 28 | RCT, Open-label | Cephalexin |
| NCT03182920 A Study of Lasmiditan in Healthy Participants | Healthy | P1 | Completed | 35 | RCT, Double-blind | Lasmiditan, Placebo |
| NCT00415636 Safety and Tolerability of IC83/LY2603618 Administered After Pemetrexed 500 mg/m2 Every 21 Days in Patients With Cancer | Cancer | P1 | Completed | 31 | Open-label | IC83/LY2603618, IC83/LY2603618, IC83/LY2603618, IC83/LY2603618, IC83/LY2603618, pemetrexed, pemetrexed |
| NCT02993471 A Study of Ixekizumab in Participants With Plaque Psoriasis | Psoriasis | P1 | Completed | 28 | Open-label | Drug Cocktail, Ixekizumab |
| NCT05395481 A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) | P1 | Completed | 115 | RCT, Double-blind | LY3849891, Placebo |
| NCT02688088 A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body | Neoplasm Metastasis | P1 | Completed | 48 | Open-label | Drug Cocktail, Abemaciclib |
| NCT03718884 A Study of Mirikizumab in Participants With Plaque Psoriasis | Psoriasis | P1 | Completed | 29 | Open-label | Drug Cocktail, Mirikizumab |
| NCT01746732 A Study of Evacetrapib in Healthy Female Participants | Healthy Volunteers | P1 | Completed | 23 | RCT, Open-label | Ortho-Cyclen, Evacetrapib |
| NCT01640249 A Study of LY3006072 in Healthy Participants | Healthy Volunteers | P1 | Terminated | 18 | RCT, Double-blind | Placebo, LY3006072 |
| NCT05533411 A Study of Donanemab (LY3002813) in Healthy Chinese Participants | Healthy | P1 | Completed | 36 | RCT, Double-blind | Donanemab, Placebo |
| NCT03375463 A Study of Tirzepatide (LY3298176) in Healthy Participants | Healthy | P1 | Completed | 52 | RCT, Double-blind | Tirzepatide, Tirzepatide, Placebo, Tirzepatide |
| NCT03343587 A Study of LY3375880 in Healthy Participants | Healthy | P1 | Completed | 80 | RCT, Double-blind | LY3375880 IV, LY3375880 SC, Placebo IV, Placebo SC |
| NCT03545087 A Study of Lanabecestat in Participants With Severe Kidney Impairment Compared to Healthy Participants | Renal Insufficiency | P1 | Withdrawn | — | Open-label | Lanabecestat, Iohexol |
| NCT01591317 Study of Prasugrel in Korean Healthy Male Volunteers | Healthy Volunteers | P1 | Completed | 30 | RCT, Open-label | Prasugrel |
| NCT01742078 A Study of LY2541546 in Healthy Postmenopausal Women | Healthy | P1 | Completed | 60 | RCT, Double-blind | LY2541546 - IV, LY2541546 - SC, Placebo |
| NCT01742091 A Multiple Dose Study of LY2541546 in Healthy Postmenopausal Women | Healthy | P1 | Completed | 59 | RCT, Double-blind | LY2541546 - SC, LY2541546 - IV, Placebo - SC, Placebo - IV |
| NCT01358968 A Drug Interaction Study to Assess the Effect of LY2603618 on the Metabolic Pathway of Desipramine | Cancer | P1 | Completed | 20 | Open-label | LY2603618, Desipramine, Pemetrexed, Gemcitabine |
| NCT02779738 A Study of Merestinib (LY2801653) in Healthy Participants | Healthy | P1 | Completed | 24 | RCT, Open-label | Merestinib |
| NCT02576951 A Study of Galcanezumab in Healthy Participants | Healthy | P1 | Completed | 178 | RCT, Double-blind | Galcanezumab, Placebo |
| NCT06908707 A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE102 in Postmenopausal Women | Postmenopausal, Healthy Adult Female Participants | P1 | Completed | 32 | RCT, Double-blind | LAE102 SC, Placebo SC, LAE102 IV, Placebo IV |
| NCT01275144 A Study of the Effect of LY2216684 on Lorazepam | Major Depressive Disorder | P1 | Completed | 28 | RCT, Double-blind | LY2216684, Placebo, Lorazepam |
| NCT06370728 A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy Participants | Healthy | P1 | Completed | 30 | Open-label | Orforglipron, Carbamazepine |
| NCT05994807 A Drug-Drug Interaction Study to Assess the Pharmacokinetics of DC-806 When Orally Administered Alone, When Coadministered With Itraconazole, and When Coadministered With Carbamazepine in Healthy Adult Participants | Healthy Volunteers | P1 | Completed | 33 | Open-label | DC-806, Itraconazole, Carbamazepine |
| NCT02497391 A Study of Different Particle Sizes of Evacetrapib in Healthy Participants | Healthy | P1 | Completed | 95 | RCT, Open-label | Evacetrapib |
| NCT01836198 The Effect of Gemfibrozil, Ketoconazole and Clarithromycin on the Amount of LY2409021 in the Bloodstream | Healthy Volunteers | P1 | Completed | 30 | RCT, Open-label | LY2409021, Gemfibrozil, Ketoconazole, Clarithromycin |
| NCT04451408 A Study of LY3372993 in Participants With Alzheimer's Disease (AD) and Healthy Participants | Alzheimer Disease, Healthy | P1 | Completed | 139 | RCT, Double-blind | LY3372993, Placebo |
| NCT03220126 A Study to Assess the Amount of LY3074828 That Gets Into the Body When Given With LY9999QS, in Healthy Participants | Healthy | P1 | Completed | 72 | RCT, Open-label | LY3074828, LY900021 |
| NCT06049108 A Study of Carbon-14-Labelled [14C] LY3871801 in Healthy Male Participants | Healthy | P1 | Completed | 8 | Open-label | [14C]-LY3871801 |
| NCT04627064 ABEMA Alone or in COMBO With MK-6482 | Clear Cell Renal Cell Carcinoma | P1 | Completed | 11 | Open-label | Abemaciclib, MK-6482 |
| NCT01825876 A Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants | Healthy Volunteers | P1 | Completed | 17 | Open-label | Evacetrapib, Warfarin |
| NCT04611789 A Study of LY3832479 (LY-CoV016) in Healthy Participants 1 | Healthy | P1 | Completed | 18 | RCT, Double-blind | LY3832479, Placebo |
| NCT05999968 Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment | Prostatic Neoplasms | P1 | Terminated | 10 | Open-label | Abemaciclib, Darolutamide, LHRH agonist/antagonist |
| NCT01286818 A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B) | Colorectal Carcinoma | P1 | Completed | 6 | Open-label | Ramucirumab (IMC-1121B), Irinotecan, levofolinate, 5-Fluorouracil (5-FU) |
| NCT06180980 A Study of the Effect of Food on Pirtobrutinib (LOXO-305) in Healthy Participants | Healthy | P1 | Completed | 20 | RCT, Open-label | Pirtobrutinib |
| NCT02745769 A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents | Advanced Cancer, Colorectal Cancer | P1 | Completed | 23 | Open-label | Ramucirumab, Merestinib, Abemaciclib |
| NCT02604160 A Study of LY3113593 in Participants With Chronic Kidney Disease | Chronic Kidney Disease | P1 | Completed | 7 | RCT, Single-blind | LY3113593, Placebo |
| NCT03073213 A Study of Ixekizumab in Chinese Participants With Psoriasis Vulgaris | Psoriasis | P1 | Completed | 32 | RCT, Open-label | Ixekizumab |
| NCT06169982 A Multiple Dose Study of LY3209590 in Participants With Type 2 Diabetes | Diabetes Mellitus, Type 2 | P1 | Completed | 56 | Open-label | LY3209590 |
| NCT06627088 A Study of LY4100511 (DC-853) Mass Balance and Absolute Bioavailability of LY4100511 in Healthy Male Participants | Healthy | P1 | Completed | 24 | Open-label | LY4100511 (DC-853), [14C]-LY4100511 (DC-853) Administered oral dose, LY4100511 (DC-853), [14C]-LY4100511 (DC-853) |
| NCT04085289 A Study of Galcanezumab (LY2951742) in Healthy Chinese Participants | Healthy | P1 | Completed | 30 | RCT, Double-blind | Galcanezumab, Placebo |
| NCT01520220 Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms | Myeloproliferative Neoplasms of, Polycythemia Vera | P1 | Completed | 100 | Open-label | LY2784544 |
| NCT05974579 Safety and Dosimetry of a New Radiotracer to Detect Misfolded SOD1 Associated With Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | P1 | Completed | 8 | Open-label | 89Zr-DFO-AP-101 |
| NCT02111083 A Study of 2 Different Formulations of Insulin Lispro in Healthy Participants | Healthy Volunteers | P1 | Completed | 38 | RCT, Double-blind | Insulin Lispro |
| NCT02806960 A Study of Single and Repeated Doses of Glucagon Administered to Participants With Diabetes | Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | P1 | Terminated | 12 | RCT, Single-blind | Nasal Glucagon |
| NCT02121834 A Study of LY3050258 in Healthy Participants | Healthy Volunteers | P1 | Completed | 63 | RCT, Double-blind | LY3050258, Placebo |
| NCT01919398 A Study of LY2940680 in Japanese Participants With Advanced Cancers | Neoplasm Metastasis | P1 | Completed | 19 | Open-label | LY2940680 |
| NCT06132126 A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus | Healthy, Type 2 Diabetes Mellitus | P1 | Completed | 66 | RCT, Double-blind | LY3938577, Placebo, Insulin degludec |
| NCT05887999 A Study of LY3532226 in Participants With Type 1 Diabetes Mellitus | Diabetes Mellitus, Type 1 | P1 | Completed | 30 | RCT, Double-blind | LY3532226, Placebo |
| NCT07247357 A Study of LY4064809 in Healthy Adult Chinese Participants | Healthy | P1 | Completed | 10 | Open-label | LY4064809 |
| NCT03305822 A Study of LY900014 in Participants With Type 2 Diabetes Mellitus | Diabetes Mellitus, Type 2 | P1 | Completed | 38 | RCT, Double-blind | LY900014, Insulin Lispro |
| NCT01330953 A First Human Study of a Ferroportin Antibody | Healthy Volunteers | P1 | Completed | 32 | RCT, Single-blind | Placebo, LY2928057 |
| NCT06173895 A Relative Bioavailability Study of LY3454738 in Healthy Participants | Healthy | P1 | Completed | 30 | RCT, Open-label | LY3454738 |
| NCT01183650 A Study of Tadalafil in Benign Prostatic Hyperplasia | Benign Prostatic Hyperplasia | P1 | Completed | 24 | Open-label | Tadalafil |
| NCT02906618 Study of LY3039478 in Healthy Participants | Healthy | P1 | Completed | 12 | Open-label | LY3039478, 13C 15N 2H-LY3039478 IV |
| NCT01236118 A Study of LY2439821 in Rheumatoid Arthritis | Rheumatoid Arthritis | P1 | Completed | 28 | Open-label | LY2439821 |
| NCT02528396 To Investigate the Efficacy and Safety of Individualized Doses of BioChaperone Insulin Lispro in Comparison to Humalog® U-100 in Patients With Type 1 Diabetes Mellitus | Type 1 Diabetes Mellitus | P1 | Completed | 36 | RCT, Double-blind | BioChaperone insulin lispro, Humalog® |
| NCT06045000 Mass Balance and Pharmacokinetics (PK) of [14C]-DC-806 in Healthy Male Participants | Healthy Volunteers | P1 | Completed | 8 | Open-label | DC-806, [14C]-DC-806 |
| NCT02759107 A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM) | Healthy, Type 2 Diabetes Mellitus (T2DM) | P1 | Completed | 142 | RCT, Double-blind | Tirzepatide, Placebo, Dulaglutide |
| NCT06945419 A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes | Healthy, Overweight | P1 | Completed | 219 | RCT, Double-blind | LY4086940, Placebo, LY4086940 |
| NCT06345794 A Study to Assess LY4100511 (DC-853) in Healthy Adult Participants | Healthy | P1 | Completed | 50 | Open-label | LY4100511 (DC-853), Itraconazole, Fluconazole, Carbamazepine |
| NCT01725451 A Study of Effect of Deodorant and Axillary Hair on Testosterone Absorption in Healthy Participants | Healthy Participants | P1 | Completed | 30 | RCT, Open-label | Testosterone |
| NCT01115751 A Study in Patients With Advanced or Metastatic Cancer | Metastases, Neoplasm | P1 | Completed | 80 | Open-label | LY2780301 |
| NCT03765502 A Study Comparing User Experience of Different Delivery Devices for Glucagon | Healthy | P1 | Completed | 99 | RCT, Open-label | IM Glucagon |
| NCT04392271 A Study of the Effects of Multiple Doses of LY3372689 on the Brain in Healthy Participants | Healthy | P1 | Completed | 4 | Open-label | LY3372689 |
| NCT02365571 A Study of LY3154207 in Healthy Participants | Healthy Participants | P1 | Completed | 64 | RCT, Double-blind | LY3154207, Placebo, Itraconazole |
| NCT06215521 A Study to Evaluate the Effect of Pirtobrutinib (LOXO-305) on QTc Interval in Healthy Participants | Healthy | P1 | Completed | 31 | RCT, Double-blind | Pirtobrutinib, Placebo, Moxifloxacin |
| NCT02018887 A Study of LY2969822 in Healthy Participants | Healthy Volunteers | P1 | Completed | 99 | RCT, Double-blind | LY2969822, Placebo |
| NCT02672423 A Study of Abemaciclib in Healthy Participants | Healthy | P1 | Completed | 127 | RCT, Open-label | Abemaciclib Capsules (Reference Formulation), Abemaciclib Tablet (Test Formulation) |
| NCT04914546 A Study of LY3819469 in Healthy Participants | Healthy | P1 | Completed | 66 | RCT, Double-blind | LY3819469, Placebo |
| NCT03222427 A Study of LY3314814 in Healthy Participants | Healthy | P1 | Completed | 8 | Open-label | LY3314814, [13C415N3] LY3314814 |
| NCT02123446 A Study of Cephalexin Capsules in Healthy Participants | Healthy Volunteers | P1 | Completed | 28 | RCT, Open-label | Cephalexin |
| NCT03748940 Study of LY3074828 in Healthy Participants | Healthy | P1 | Completed | 60 | RCT, Double-blind | LY3074828, Placebo, LY900021 |
| NCT01771250 A Study of Insulin Peglispro and Glargine on Fats in Participants With Type 1 Diabetes | Diabetes Mellitus, Type 1 | P1 | Completed | 15 | RCT, Open-label | Insulin Peglispro, Insulin Glargine |
| NCT04050670 A Study of Tirzepatide at Different Injection Sites in Participants With Different Body Sizes | Healthy | P1 | Completed | 54 | RCT, Open-label | Tirzepatide |
| NCT03148431 A Study of LY3002815 in Healthy Participants | Healthy | P1 | Terminated | 45 | RCT, Double-blind | LY3002815, Placebo |
| NCT01821703 A Study of LY3045697 After Multiple Oral Dosing in Healthy Participants | Healthy Volunteers | P1 | Completed | 24 | RCT, Double-blind | LY3045697, Placebo, Spironolactone, Placebo |
| NCT03009162 Study of Oral Lasmiditan in Participants With Normal and Impaired Renal Function | Migraine | P1 | Completed | 16 | Open-label | Lasmiditan |
| NCT00576394 Aggressive Versus Moderate Glycemic Control in Diabetic Coronary Bypass Patients | Glycemic Control | P1 | Completed | 108 | RCT, Single-blind | IV Insulin drip, Insulin |
| NCT01284335 A Safety Study in Participants With Advanced Solid Tumors | Advanced Solid Tumors | P1 | Terminated | 234 | Open-label | Gemcitabine, Docetaxel, Temozolomide, Cisplatin, Erlotinib, LY573636 |
| NCT04515576 A Study of LY3493269 in Participants With Type 2 Diabetes | Diabetes Mellitus, Type 2 | P1 | Completed | 56 | RCT, Double-blind | LY3493269, Dulaglutide, Placebo |
| NCT02046304 PP-Gemcitabine & External Beam Radiation-Sarcomas | Sarcoma | P1 | Completed | 41 | Open-label | Gemcitabine |
| NCT00277706 Impact of Parathyroid Hormone (PTH) on Osseous Cavity | Bone Loss, Periodontitis | P1 | Completed | 40 | RCT, Double-blind | FORTEO, Placebo |
| NCT01346358 A Study of IMC-CS4 in Subjects With Advanced Solid Tumors | Neoplasms | P1 | Completed | 52 | Open-label | IMC-CS4 |
| NCT01300260 Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose | Diabetes Mellitus, Type 2 | P1 | Completed | 32 | RCT, Double-blind | LY2189265, Placebo, Insulin, Glucose, Glucagon |
| NCT04682106 A Study of LY3493269 in Healthy Participants | Healthy | P1 | Completed | 40 | RCT, Double-blind | LY3493269, Placebo, Salcaprozate Sodium |
| NCT05630274 A Study of Effect of Selpercatinib (LY3527723) on Corrected QT (QTc) Interval in Healthy Participants | Healthy | P1 | Completed | 32 | RCT, Double-blind | Selpercatinib, Moxifloxacin, Placebo |
| NCT01995526 A Study of Insulin Peglispro in Healthy Male Japanese Participants | Healthy Volunteers | P1 | Completed | 11 | Open-label | Insulin Peglispro |
| NCT01688635 A Study to Compare LY2963016 and US-approved Lantus® After Single Dose Administration to Healthy Participants | Healthy | P1 | Completed | 91 | RCT, Double-blind | LY2963016, US Approved Lantus |
| NCT03407118 A Study of LY900014 in Japanese Participants With Type 1 Diabetes Mellitus | Diabetes Mellitus, Type 1 | P1 | Completed | 31 | RCT, Double-blind | LY900014, Insulin Lispro |
| NCT05042310 A Study of LY3541860 in Healthy Japanese and Non-Japanese Participants | Healthy | P1 | Completed | 94 | RCT, Double-blind | LY3541860, Placebo |
| NCT01870297 A Study of LY3025876 in Participants With Diabetes | Type 2 Diabetes Mellitus | P1 | Completed | 72 | RCT, Double-blind | LY3025876, Placebo, Liraglutide |
| NCT01925989 A Study of How Insulin Peglispro (LY2605541) and Insulin Glargine Affect the Breakdown of Fat and Sugar in Type 1 Diabetics | Type 1 Diabetes Mellitus | P1 | Completed | 27 | RCT, Open-label | LY2605541, Insulin Glargine |
| NCT03019536 A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease | Alzheimer Disease | P1 | Completed | 22 | RCT, Double-blind | LY3303560 - IV, Placebo - IV, Florbetapir F 18, Flortaucipir F18 |
| NCT05630287 A Study of Absorption, Metabolism, Excretion, and Absolute Bioavailability of Carbon-14-Labelled [14C] Selpercatinib (LY3527723) in Healthy Male Participants | Healthy | P1 | Completed | 12 | Open-label | [14C]-Selpercatinib, Selpercatinib, [14C]-Selpercatinib |
| NCT01682135 A Study in Participants With Advanced Solid Tumors | Solid Tumor | P1 | Completed | 28 | Open-label | Ramucirumab |
| NCT07519525 A Study of [14C]-LY4064809 in Healthy Participants | Healthy | P1 | Completed | 7 | Open-label | LY4064809, [14C]-LY4064809 |
| NCT04881747 A Study to Compare Two Different Formulations of Lasmiditan in Healthy Participants | Healthy | P1 | Completed | 47 | RCT, Open-label | Lasmiditan |
| NCT02555449 A Study of [¹⁴C]-LY3202626 in Healthy Male Participants | Healthy | P1 | Completed | 6 | Open-label | [¹⁴C]-LY3202626 |
| NCT01569126 A Study of LY110140 in Healthy Japanese Male Participants | Healthy Volunteer | P1 | Completed | 56 | RCT, Double-blind | LY110140, Placebo |
| NCT05841277 A Study of LY3819469 in Participants With Impaired and Normal Renal Function | Renal Insufficiency, Healthy | P1 | Completed | 26 | Open-label | LY3819469 |
| NCT02084082 Bioequivalence of a FDC Tablet of Linagliptin/Metformin (5mg/1000mg) Extended Release in Healthy Subjects | Healthy | P1 | Completed | 68 | RCT, Open-label | Linagliptin/Metformin ER FDC, Linagliptin, Metformin ER |
| NCT03367390 A Study of an Automated Insulin Delivery System in Participants With Type 1 Diabetes Mellitus (T1DM) | Type1 Diabetes Mellitus | P1 | Completed | 30 | Open-label | Insulin Lispro |
| NCT00185575 Duloxetine for the Treatment of Dysthymia | Depressive Disorder | N/A | Completed | 24 | Open-label | duloxetine |
| NCT00136929 Senior PAMI: Primary Angioplasty Versus Thrombolytic Therapy for Acute Myocardial Infarction in the Elderly | Myocardial Infarction | N/A | Unknown | 530 | RCT, Open-label | Thrombolytic therapy |
| NCT05577169 Incorporating Mind-body Skills With Diabetes Education in Adolescents With Type 1 Diabetes | Type 1 Diabetes, Adolescent Behavior | N/A | Completed | 30 | RCT, Open-label | — |
| NCT00953862 Atomoxetine/Attention Deficit/ Hyperactive Disorder (ADHD)/Substance Use Disorder (SUD)in a Residential Treatment Facility | Attention Deficit Hyperactivity Disorder | N/A | Completed | 18 | Open-label | Atomoxetine |
| NCT03986502 Financial Navigation Intervention in Improving Financial and Clinical Outcomes in Patients With Newly Diagnosed Gastric or Gastroesophageal Junction Adenocarcinoma | Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | N/A | Completed | 30 | RCT, Open-label | — |
| NCT01724580 Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes | Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE), Juvenile Dermatomyositis (JDM) | APPROVED_FOR_MARKETING | — | — | Baricitinib | |
| NCT01117831 An Analysis of Diabetes Control in Puerto Rico | Diabetes Mellitus, Arterial Hypertension | Completed | 600 | — | — | |
| NCT07675057 Expanded Access for Vepugratinib (LY3866288) in Participants With Fibroblast Growth Factor Receptor 3 (FGFR3) Altered Solid Tumors | Urinary Bladder Neoplasms, Neoplasm Metastasis | AVAILABLE | — | — | Vepugratinib | |
| NCT02890121 Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases: | Systemic Autoimmune Diseases | Completed | 2,006 | — | — | |
| NCT01055808 Observational Study in Japanese Type 2 Diabetes Patients | Diabetes Mellitus, Type 2 | Completed | 677 | — | Insulins | |
| NCT01080313 Head and Neck Cancer Registry (LORHAN) | Head and Neck Cancer | Completed | 26,000 | — | — | |
| NCT00307268 Evaluating Clinical Outcomes of Treatment Effectiveness for Children and Adults With ADHD | Attention-Deficit/Hyperactivity Disorder (ADHD) | Completed | 195 | — | — | |
| NCT07503613 Long Term Follow-up Study of AAVAnc80-antiVEGF Gene Therapy | Vestibular Schwannoma | By Invite | 100 | — | — | |
| NCT00211263 Bipolar Disorder Research Study for Ages 12 and Older | Bipolar Disorder | N/A | Completed | 750 | RCT, Open-label | mood stabilizer |
| NCT03338803 Real World Glycemic Effectiveness of Linagliptin | Diabetes Mellitus, Type 2 | Completed | 11,001 | — | Linagliptin | |
| NCT01787903 The Effects of RT-CGM on Glycemia and QoL in Patients With T1DM and IHA | Type 1 Diabetes Mellitus, Hypoglycemia Unawareness | N/A | Completed | 52 | RCT, Open-label | — |
| NCT01067794 Chemotherapy in Treating Patients With Lung Cancer | Non Small Cell Lung Cancer | Completed | 1,610 | — | Any platinum-based doublet chemotherapy | |
| NCT03849612 A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus | Type 1 Diabetes Mellitus | N/A | Completed | 10 | Open-label | Insulin Lispro |
| NCT01109472 Improving Osteoporosis Care in a Home Health Setting | Osteoporosis | N/A | Completed | 1,009 | RCT, Single-blind | — |
| NCT00712660 Study With Information Technology (IT) - Aided Preventive Program in Schizophrenia | Schizophrenia | N/A | Completed | 146 | RCT, Double-blind | antipsychotic dose increase |
| NCT00824603 Impact of Continuing Medical Education (CME) Insulin Program | Diabetes | Completed | 294 | — | — | |
| NCT03559088 A Study of the Effect of a Disease-Specific Migraine Smart Phone Application (App) on Participant Care | Migraine | N/A | Completed | 120 | Open-label | — |
| NCT04681768 Abemaciclib in Combination With Endocrine Therapy as First Line Therapy in Metastatic Breast Cancer Patients | Breast Cancer/ Metastatic Breast Cancer | Completed | 95 | — | Abemaciclib | |
| NCT00934908 Prevention of Weight Gain and Dyslipidemia by Green Tea in Patients Initiating Therapy With Olanzapine | Bipolar Disorder, Schizophrenia | N/A | Withdrawn | — | RCT, Double-blind | — |
| NCT01056549 Exenatide (Byetta ®) Regulation of Intestinal and Hepatic Lipoprotein Particle Production in Humans | Hyperlipidemia | N/A | Completed | 15 | RCT, Single-blind | exenatide |
| NCT01354015 Diabetes Remote Care Management System | Diabetes | N/A | Completed | 98 | RCT, Open-label | — |
| NCT03830840 Mil Familias Cohort Establishment: a Study to Understand Determinants of Diabetes and Its Complications Among US Latinos | Type2 Diabetes Mellitus, Cardiovascular Diseases | Completed | 405 | — | — | |
| NCT01078805 Study of FORTEO Use in Subjects in the Community Setting | Osteoporosis | Completed | 4,167 | — | FORTEO | |
| NCT03652272 Development and Evaluation of an Electronic Health Record-based Medication Complete Communication (EMC2) Strategy | Medication Adherence | N/A | Completed | 301 | RCT, Open-label | — |
| NCT02890134 Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases: Inception Cohort | Systemic Autoimmune Diseases | Completed | 215 | — | — |